

Chugai Pharmabody Research At the forefront of global research Established in 2012, CPR is a subsidiary of Chugai Pharmaceutical

Driven by a desire to improve patients' lives



CPR discovers drugs to tackle unmet medical needs:



Cancer



CYCLIC PEPTIDE TECHNOLOGY


Inflammatory diseases



Fibrotic diseases



Genetic diseases



Always a step ahead of others by redefining the approach to drug discovery

Unlike conventional antibody technology which limits druggable targets, our proprietary technologies enable us to expand the drug target universe

Our proprietary technologies expand the drug universe

Antibody Engineering Technology



Recycling **Antibody**® **Technology**

unlike conventional

antibodies which can only bind once

allows a single antibody molecule to bind multiple times to an antigen

Bispecific Antibody **Technology**

two different antigens

at the same time

enables unique modes of action by binding to

Switch Antibodv™ **Technology**



Sweeping **Antibody**® **Technology**

allows a recycling antibody to efficiently sweep away and eliminate antigens from the plasma which cannot be achieved by conventional antibodies


Technology

potently kills cancer cells by binding to various tumor antigens and redirecting T cells to eliminate them





We are pioneers in mid-size molecule drug discovery -



Location

Singapore 138623

3 Biopolis Drive #07-11 to 16, Synapse



Contact details

: +65 6933 4888

contact@chugai-pharmabody.com



